-
Precision-engineered profits: How to invest in genomics
Developments in genomics are enabling the rise of personalised medicine, with therapies tailored specifically for individuals. Smart investors should buy in now, says Matthew Partridge
-
Anne Wojcicki: the daring 23andMe CEO who reached too far
Profile Anne Wojcicki dreamed of a revolution in personal genomics and medicine and set up 23andMe in 2006. Its collapse into bankruptcy provides a cautionary tale
Profile -
Cash in on the biotech sector with specialist BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
Opinion -
How to invest in weight-loss drugs
The new generation of weight-loss drugs are a boon for the overweight, but they also promise to change our relationship with food and revolutionise the economy
-
Vertex Pharmaceuticals is a rare opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
-
Investment opportunities in supporting an ageing population
Ageing populations have prompted fruitful research in sectors ranging from pharmaceuticals and medical equipment to glasses and hearing aids
-
AstraZeneca goes cheap – should you buy?
The decline in AstraZeneca’s share price is overdone given the outlook, and the stock is cheap
-
Vaccine maker shares slump after Trump picks RFK Jr as next US health secretary
Drugmakers' shares slumped after RFK Jr, a vaccine sceptic, was appointed as the next US Health Secretary. How will this affect drug companies?
-
Investing in pharmaceutical companies? The pipeline is key
A strong pipeline is all-important for pharmaceutical companies. We highlight the most interesting candidates.
